<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-MedLine.d28">
    <sentence id="DDI-MedLine.d28.s0" text="New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.&#xa;">
        <entity id="DDI-MedLine.d28.s0.e0" charOffset="53-62"
            type="group" text="glitazones"/>
    </sentence>
    <sentence id="DDI-MedLine.d28.s1" text="Type 2 diabetes mellitus is a growing problem not only in the United States but also across the world. "/>
    <sentence id="DDI-MedLine.d28.s2" text="There is now strong evidence that intensive control of blood glucose can significantly reduce and retard the microvascular complications of retinopathy, nephropathy, and neuropathy. "/>
    <sentence id="DDI-MedLine.d28.s3" text="Ultimately however, up to 80% of type 2 diabetics die from macrovascular cardiovascular disease. "/>
    <sentence id="DDI-MedLine.d28.s4" text="This increased incidence of atherosclerotic disease is intricately associated with insulin resistance, which is a major pathophysiologic abnormality in type 2 diabetes. "/>
    <sentence id="DDI-MedLine.d28.s5" text="There is strong evidence that insulin resistance is involved in the development of not only hyperglycemia, but also dyslipidemia, hypertension, hypercoagulation, vasculopathy, and ultimately atherosclerotic cardiovascular disease. "/>
    <sentence id="DDI-MedLine.d28.s6" text="This cluster of metabolic abnormalities has been termed the insulin resistance or cardiovascular dysmetabolic syndrome. "/>
    <sentence id="DDI-MedLine.d28.s7" text="The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are &quot;insulin sensitizers&quot; ">
        <entity id="DDI-MedLine.d28.s7.e0" charOffset="4-21"
            type="group" text="thiazolidinediones"/>
        <entity id="DDI-MedLine.d28.s7.e1" charOffset="24-36"
            type="drug" text="rosiglitazone"/>
        <entity id="DDI-MedLine.d28.s7.e2" charOffset="42-53"
            type="drug" text="pioglitazone"/>
        <entity id="DDI-MedLine.d28.s7.e3" charOffset="77-95"
            type="group" text="antidiabetic agents"/>
        <pair id="DDI-MedLine.d28.s7.p0" e1="DDI-MedLine.d28.s7.e0"
            e2="DDI-MedLine.d28.s7.e1" ddi="false"/>
        <pair id="DDI-MedLine.d28.s7.p1" e1="DDI-MedLine.d28.s7.e0"
            e2="DDI-MedLine.d28.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d28.s7.p2" e1="DDI-MedLine.d28.s7.e0"
            e2="DDI-MedLine.d28.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d28.s7.p3" e1="DDI-MedLine.d28.s7.e1"
            e2="DDI-MedLine.d28.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d28.s7.p4" e1="DDI-MedLine.d28.s7.e1"
            e2="DDI-MedLine.d28.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d28.s7.p5" e1="DDI-MedLine.d28.s7.e2"
            e2="DDI-MedLine.d28.s7.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d28.s8" text="and exert direct effects on the mechanisms of insulin resistance. "/>
    <sentence id="DDI-MedLine.d28.s9" text="These effects not only improve insulin sensitivity and glycemic control with reduced insulin requirements, but also have potentially favorable effects on other components of the cardiovascular dysmetabolic syndrome. "/>
    <sentence id="DDI-MedLine.d28.s10" text="Long-term studies are needed to determine whether the insulin-sensitizing effects of the glitazones can prevent or delay premature atherosclerotic cardiovascular disease, morbidity, and death.">
        <entity id="DDI-MedLine.d28.s10.e0" charOffset="89-98"
            type="group" text="glitazones"/>
    </sentence>
</document>
